Market Overview - On July 1, A-shares experienced a slight upward movement with a total transaction volume of 1.49 trillion yuan, where over 2,600 stocks rose, indicating a generally bullish market sentiment [1] - Leading sectors included pharmaceuticals, biological products, precious metals, and banking, while sectors such as diversified finance, software development, telecommunications, and batteries saw the largest declines [1] Options Market Activity - The options market saw a decrease in transaction volume but a steady increase in open interest, with total transactions amounting to 3.7281 million contracts, down 19.20% from the previous trading day, while total open interest rose by 8.42% to 7.3985 million contracts [1] - The Shanghai Stock Exchange 50 ETF options recorded a transaction volume decrease of 19.56% and an open interest increase of 8.23%, with 605,600 contracts traded, down from 752,900 contracts [1] Options Position Changes - For the July contracts, there was a total increase of 55,400 contracts in open interest, with call options increasing by 20,000 contracts and put options by 35,400 contracts, indicating a preference for both call and put options in slightly out-of-the-money positions [1] - The CSI 300 ETF options mirrored the trends of the Shanghai 50 ETF options, with transaction volumes decreasing by 29.05% for the Shenzhen Stock Exchange and 21.86% for the Shanghai Stock Exchange, while open interest increased by 11.19% and 10.67% respectively [2] Volatility Analysis - The implied volatility for the Shanghai 50 ETF at the end of July 1 was 11.62%, with historical volatility remaining low at 8.48% for the 30-day period [3] - The overall analysis suggests that the A-share market is in a consolidation phase following a volume increase, with both call and put options being added in slightly out-of-the-money positions, indicating a cautious outlook for short-term market movements [3]

Group 1 - The company has nominated Huang Juan as an independent director candidate for its fourth board of directors, confirming her independence and compliance with relevant regulations [1][2][3] - Huang Juan has undergone qualification review by the company's nomination committee and has no relationships that could affect her independent performance [1][2] - The candidate has confirmed that she meets the qualifications and conditions set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange for independent directors [2][3][4] Group 2 - The company has also nominated Zhang Jianping as an independent director candidate, who has agreed to the nomination and confirmed his independence [29][58] - Zhang Jianping has passed the qualification review and has no conflicts of interest that could impact his independent duties [29][58] - The nomination is based on a thorough understanding of Zhang Jianping's professional background, qualifications, and absence of any significant credit issues [29][58]

Core Viewpoint - Shenzhen Weiguang Biological Products Co., Ltd. is undergoing a board re-election process in accordance with relevant laws and regulations, with the nomination of candidates for the fourth board of directors [1][2]. Group 1: Board Election Process - The third board of directors held its thirty-fourth meeting on July 1, 2025, and approved the proposals for the re-election of the board and the nomination of candidates for both non-independent and independent directors [2]. - The candidates for the fourth board include five non-independent directors and three independent directors, with their qualifications having been reviewed by the board's nomination committee [2][3]. - The election will be conducted at the company's first extraordinary general meeting of 2025, using a cumulative voting system to elect eight directors, alongside one employee representative director [2][3]. Group 2: Candidate Qualifications - Zhang Zhan, the current chairman, has a graduate degree and is a senior engineer, with a history of serving in various roles within the company [3][4]. - Guo Caiping, the current general manager, holds a doctoral degree and has been with the company since 1994, having held multiple positions [5][6]. - Chen Guanqun, the financial director, is a senior accountant with a bachelor's degree in economics and has experience in various financial roles [6][7]. - Li Ligan, a current director, has a bachelor's degree and serves as the financial director at another company [7][8]. - Zhang Xianen, a biotechnology expert, has extensive academic qualifications and has held significant positions in research institutions [8][9]. - The independent director candidates, including Wang Yanmei, Huang Juan, and Zhang Jianping, have relevant academic and professional backgrounds, ensuring they meet the independence criteria [9][10].

Core Viewpoint - Shenzhen Weiguang Biological Products Co., Ltd. has revised its Articles of Association and related systems to enhance corporate governance and operational standards [1][2]. Group 1: Articles of Association Revision - The company has proposed amendments to its Articles of Association to improve governance structure and comply with relevant laws and regulations [1]. - The revised Articles of Association and a comparison table of changes are available on the official website [1]. Group 2: Related System Revisions - The board of directors has approved revisions to several internal systems, including those related to independent directors, audit committee, nomination committee, compensation and assessment committee, strategic committee, insider information management, and accountant selection [1]. - The full text of the revised systems is also published on the official website [1].

Core Points - The company has approved the implementation of the third employee stock ownership plan [1][2] - The lock-up period for the employee stock ownership plan will expire on July 7, 2025 [1] - The plan has completed the purchase of company shares through the secondary market as of July 3, 2024 [1] Summary of Employee Stock Ownership Plan - The employee stock ownership plan will have a lock-up period of 12 months from the date of the last share transfer [1] - After the lock-up period, the management committee will decide on the timing of selling the shares held by the plan [1][2] - The plan will comply with market trading rules and relevant laws and regulations [1] Duration, Changes, and Termination of the Plan - The duration of the employee stock ownership plan starts from the date of the last share transfer to the plan [2] - Changes to the plan require approval from at least two-thirds of the participating holders [2] - The plan can be terminated early under certain conditions, including the inability to liquidate all shares before the expiration of the duration [2]

Core Viewpoint - The independent director candidate Wang Yanmei has declared her commitment and qualifications to serve on the fourth board of Shenzhen Weiguang Biological Products Co., Ltd, ensuring her independence and compliance with relevant regulations [1][2][3]. Group 1 - The candidate has confirmed that there are no relationships with the company that could affect her independence [1]. - The candidate has passed the qualification review by the company's nomination committee and has no conflicts of interest with the nominator [1]. - The candidate meets the qualifications and conditions for independent directors as stipulated by the China Securities Regulatory Commission and Shenzhen Stock Exchange [1][2]. Group 2 - The candidate has participated in training and obtained relevant certification recognized by the stock exchange [2]. - The candidate has no violations of laws or regulations that would disqualify her from serving as an independent director [2][3]. - The candidate has the necessary knowledge and experience related to the operation of listed companies, with over five years of relevant work experience [3][4]. Group 3 - The candidate and her immediate family do not hold any shares in the company or its subsidiaries [4][5]. - The candidate has not been subject to any disqualifications or penalties by regulatory authorities in the past three years [5][6]. - The candidate has committed to report any changes in her qualifications during her tenure as an independent director [6][7].

证券分析师：张冬冬 E-MAIL：zhangdd@tpyzq.com 分析师登记编号：S1190522040001 证券分析师：吴步升 E-MAIL：wubs@tpyzq.com 分析师登记编号：S1190524110002 大类资产跟踪 债券市场：利率债涨跌不一，短端几乎持平，长端上涨。股市方面上 证指数放量突破颈线压制，且呈均线排列结构，虽然基本面的疲弱仍将支 撑债市，但股市若继续走强仍将压制债市表现，预计债市后续将高位震荡 运行。后续展望：股市大盘突破，债市预计高位震荡。 2025 年 07 月 01 日 投资策略 策略日报（2025.07.01）：指数分化 相关研究报告 <<策略日报（2025.06.30）：创业板指 领涨>>--2025-07-01 A 股：三大指数分化，沪指领涨，创新药概念爆发。市场全天成交额 1.49 万亿，较前一日缩量 0.02 万亿，个股涨跌分化，2514 只个股上涨， 2394 只个股下跌。沪指技术面上指数突破了 3 月份的高点，上涨空间已 经打开。有三个观察点来判断行情的强弱支撑是否有效：一是前期油价的 高点也是地缘风险消退和指数止稳的起点，因此 6 月 23 日上涨的低 ...

Core Viewpoint - The company, Jiao Da Ang Li, has reported criminal actions against five former executives for allegedly harming the company's interests by using company funds to purchase group insurance and subsequently refunding the premiums to personal accounts [1][2][3]. Group 1: Background of the Incident - The five former executives involved are Yang Guoping, Zhu Minjun, Lou Jianying, Li Hong, and Li Kangming, who held various senior positions in the company from 2016 to 2019 [5][6]. - The company filed a criminal report with the Shanghai Public Security Bureau, transitioning from a civil lawsuit to address the alleged criminal behavior discovered during the civil proceedings [3][16]. Group 2: Details of the Insurance Transactions - The first group insurance policy was taken out in October 2016 with a total premium of 3.8 million yuan, and the beneficiaries included the five former executives [6][12]. - In November 2017, the company applied for a refund of the insurance premium, which was directly returned to the personal accounts of the five executives, totaling 1.0936 million yuan [14][17]. - A second insurance policy was purchased in 2018 for a total of 12.84 million yuan, which was also refunded to the personal accounts of the same executives in January 2019 [14][15]. Group 3: Company’s Response and Findings - The current management, led by Ji Lin, discovered these irregularities during a self-audit prompted by a tax authority inquiry into the insurance premiums [20][21]. - The management found no records of board resolutions or approval processes for these transactions, raising concerns about their legality [16][20]. - Legal experts noted that using group insurance to refund premiums to executives' personal accounts is an unusual practice and could indicate potential misconduct [18][21].

Market Overview - The market experienced fluctuations with mixed performance among the three major indices, where the Shanghai Composite Index rose by 0.39%, the Shenzhen Component Index increased by 0.11%, while the ChiNext Index fell by 0.24% [1] Sector Performance - Sectors such as glass fiber, chemical pharmaceuticals, and biological products showed significant gains, while multi-financial, software development, and battery sectors faced declines [1] - Major capital inflows were observed in the chemical pharmaceuticals, electric power, and banking sectors [1] Innovation Drug Sector - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, emphasizing the use of medical insurance data for drug research and development [2] - According to Guojin Securities, the innovative drug sector is currently undervalued, with an increase in the number and quality of new drug approvals in China since the beginning of 2025 [2] Gold Market Outlook - U.S. President Trump criticized the Federal Reserve for not lowering interest rates, with expectations of a rate cut later this year and three cuts next year [3] - China Galaxy Securities predicts that COMEX gold prices may steadily break through $3,300 per ounce, with potential to reach $3,500 in extreme risk scenarios [3] Banking Sector Analysis - The People's Bank of China indicated a continuation of accommodative monetary policy, with expectations for further interest rate cuts and a potential reserve requirement ratio reduction [3] - Guosheng Securities highlighted the ongoing attractiveness of the banking sector, citing a dividend yield of 5.13% compared to a 10-year government bond yield of 1.66%, indicating a significant yield spread [4]

Core Viewpoint - Zhong Shanshan, known as the "Mineral Water King," has made significant investments in coconut water and collagen products, indicating a strategic shift towards health and wellness sectors amidst fluctuating fortunes in his previous ventures [2][3][4]. Investment in IF Coconut Water - Zhong Shanshan invested in IF Coconut Water, which debuted on the Hong Kong Stock Exchange with a 58% increase on its first day, leading to a paper profit of over 18 million HKD within three days [2][4][6]. - The company primarily targets the Chinese market, with 92.4% of its sales coming from there, showcasing a strong alignment with consumer health trends [7]. Investment in Jinbo Biotechnology - Zhong also invested 3.4 billion CNY in Jinbo Biotechnology, a company specializing in high-margin collagen beauty products, achieving a gross margin of 92% [8][10]. - Following the investment, Zhong became the second-largest shareholder, controlling 10.58% of the company, which is positioned for future growth and potential listing on major stock exchanges [10][11]. Business Strategy and Empire - Zhong's business strategy is characterized by a diversified portfolio that includes health products, functional beverages, and biotechnology, aiming to create a "big health empire" [11][12]. - His investment approach is marked by a focus on long-term, controllable projects rather than speculative ventures, emphasizing the importance of sustainable profitability [14][22]. Historical Context and Personal Background - Zhong Shanshan's rise to wealth began with the establishment of Yangshengtang, focusing on health products, followed by the launch of Nongfu Spring, which capitalized on the growing demand for natural bottled water [18][19]. - His background as a self-made entrepreneur, starting from humble beginnings, has shaped his pragmatic approach to business and investment [15][20]. Conclusion - Zhong Shanshan's ability to rebound from financial setbacks is attributed to his consistent focus on viable products and markets, rather than fleeting trends, positioning him as a resilient figure in the investment landscape [20][21].